module.exports = {
  jobCode: `EVZ_2021_0060_UK <br/>OCTOBER 2021`,
  disclaimer: `
    For Healthcare Professionals Only<br/>
    <span class="highlight-primary">Click here for UK Prescribing Information and Adverse Event Reporting</span>
  `,
  slides: [
    {
      content: `
        <h2 class="prelude">EVRENZO (roxadustat) is indicated for treatment of adult <br/>patients with symptomatic anaemia associated with CKD<sup>1</sup></h2>
        <h1 class="title">In anaemia of chronic kidney disease (CKD), <br/>the treatment landscape is changing</h1>
      `,
      background: {
        image: `url(${require("./assets/background.jpg")})`,
      },
      timeout: 4000,
    },
    {
      content: `
        <h1 class="title">Follow a new pathway to <br/>treat anaemia of CKD…</h1>
      `,
      background: {
        image: `url(${require("./assets/background.jpg")})`,
      },
      timeout: 4000,
    },
    {
      content: `
        <h1 class="title">EVRENZO™ harnesses the HIF pathway to <br/>stimulate erythropoiesis<sup>1,2</sup> </h1>
        <ul>
            <li>HIF (hypoxia-inducible factor) is a central regulator of erythropoiesis<sup>3</sup></li>
            <li>EVRENZO is the first treatment to activate the HIF pathway<sup>4</sup></li>
            <li>Through this action, EVRENZO mimics the body’s natural response to hypoxia<sup>2</sup></li>
        </ul>
      `,
      background: {
        color: `#007A33`,
      },
      timeout: 4000,
    },
    {
      content: `4`,
      background: {
        color: `#007A33`,
      },
      timeout: 3000,
    },
  ],
};
